Dolutegravir leads to weight gain in two African studies

IAS 2019: Conference on HIV Pathogenesis Treatment and Prevention, Mexico City, July 21-24 2019

Higher Immune Activation With Methadone Than Naltrexone in Opioid Users With HIV

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Substance Use--Especially Meth--Tied to Depression in Young HIV+/HIV- MSM

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Neural Tube Defect Rate 0.40% With Dolutegravir in Pregnancy--But Data Still Slim

IAS 2019: Conference on HIV Pathogenesis Treatment and Prevention, Mexico City, July 21-24 2019

HIV.gov’s Facebook live conversations at IAS

IAS 2019: Conference on HIV Pathogenesis Treatment and Prevention, Mexico City, July 21-24 2019

Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV

Gilead | July 22, 2019

Out-of-Care HIV+ US MSM Will Resume Treatment, But Only Half Control HIV in 12 Months

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Gilead Announces Latest Data in Ongoing HIV Cure Research Program

Gilead | July 23, 2019

Lower HIV Rate With F/TAF Than F/TDF in Double-Blind Noninferiority Trial

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Higher GI Disorder Risk When Switching to RAL or DRV Versus DTG

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

High STI Prevalence in German MSM, But Low Rates of HIV, HCV, HBV

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

About 10% With HIV in Europe Have Heavy Treatment Experience, Few Options

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019

Merck | July 24, 2019

Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Better Predictive Power When Combining Traditional and HIV-Specific Cardio Risk Factors

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Out-of-Care HIV+ US MSM Will Resume Treatment, But Only Half Control HIV in 12 Months

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

DMPA May Have STI Advantage Over Copper IUD and Levonorgestrel Implant

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Virologic efficacy of raltegravir vs. efavirenz-based antiretroviral treatment in HIV1-infected adults with tuberculosis: W48 results of the ANRS 12300 REFLATE TB2 trial

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

 

Meta-Analysis Confirms Aerobic Exercise Benefit on Depression With HIV

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Inflammatory Marker and Immune Upsets After Single Forced Vaginal Penetration

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

More Acute HIV Diagnoses, Shorter Time to Undetectable HIV, in Amsterdam MSM Program

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

WHO recommends dolutegravir as preferred HIV treatment option in all populations

IAS 2019: Conference on HIV Pathogenesis Treatment and Prevention, Mexico City, July 21-24 2019

Week-96 Potency of Dolutegravir/3TC in GEMINI Trials of First-Line ART

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Breaking Survey Data: Public Opinion on HIV Policy in Seven Southern States

NC AIDS Action | July 24, 2019

Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®

Gilead | July 23, 2019

HIV Infection Rate Jumps 7.5-fold When US PrEP Users Stop

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Neural Tube Defect Rate 0.40% With Dolutegravir in Pregnancy--But Data Still Slim

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Young Men Driving Expanding HIV Epidemic in Latin America

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Sharp Drops in HIV Load After 10 Days of Capsid Inhibitor Monotherapy

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Viral Suppression in 60% for 96 Weeks With Fostemsavir Salvage in BRIGHTE

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Vision Impairment More Frequent in Older HIV+ Men--With Functional Consequences 

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

Risk of neural tube defects slightly higher for babies of women on HIV therapy containing dolutegravir

NIH | July 22, 2019

Almost No New HIV Infections in Paris Comparison of Daily vs As-Needed PrEP

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City

HIV Control Rate Lower in Women Than Men in Inner-City Vancouver

10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City